Fundraising Fox
DCVC Bio
Venture capitalPalo Alto · Seed–Growth · 16 people tracked
Find your way into DCVC Bio
Each arrow is one introduction. Sign up to fill in the first one.
Ask Jamie Watson to introduce you to Matt Ocko
You →Jamie · together at Sevin Rosen Funds →Matt
Ask Jamie Chen to introduce you to Richard Waines
You →Jamie · together at DCVC Bio →Richard
Ask Sam Okafor to introduce you to Kiersten Stead
You →Sam · together at Nilo Therapeutics →Kiersten
- John Hamer343 people can intro you
- Dr. Justin Kern6 people can intro you
- Zachary Bogue2 people can intro you
Sign up to find every way you can get introduced to DCVC Bio
- Your email: who you already know at DCVC Bio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the DCVC Bio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
DCVC Bio invests in founders marrying deep biological insight and engineering with large-scale computation to solve hard problems. Established in 2018, it backs foundational science and deep tech ventures across drug discovery (using synthetic biology, microfluidics, and machine learning to create novel therapies), agriculture (safer crop protection, reduced fertilizer use, renovated food systems), and bio-based alternative materials. The firm's team combines scientific expertise in genetics, chemistry, molecular biology, agriculture, industrial fermentation, and AI with decades of operational management experience, aiming to improve human health, make food production more sustainable, and slow climate change.
Source: firm website, verified Aug 24, 2026.
Team · 16 people
from the firm's website & curated
Founder mafia
5 people who came through DCVC Bio went on to found or lead other companies.
What they invest in
from 32 of 38 portfolio companiesBiotech ×24AI & Machine Learning ×15Deep Tech ×14Healthtech ×8Medical Devices ×5AgTech ×4Climate Tech ×4Media & Entertainment ×4
HQs:United States×24Australia×1
Investments · 38 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 62024 · 22023 · 62022 · 52021 · 42016 · 127 dated
Fervo Energy develops next-generation geothermal technology using advanced drilling and sensing techniques to unlock carbon-free, 24/7 power generation in previously uneconomic locations.
CleantechClimate TechEnergyHouston, US
Tim Latimer(Founder)inJack Norbeck(Founder)in
BoardDavid Thomas Danielson(Director)inNicholas Walrod(Director)inIon Yadigaroglu(Director)
Co-investorsB Capital GroupB4 CapitalBaruch Future VenturesBeast VenturesBreakthrough Energy VenturesCarbon+16 more
.jpeg){kind=logo}
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)Andrew Scharenberg(Founder)Michael Jensen(Founder)Philip Low(Founder)Ryan Crisman(Founder)
Board seatJohn Hamer· per SEC Form D
Co-investorsMPM BioImpactQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundAlexandria+2 more
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Founder)Young Kwon(Founder)
Co-investorsRA CapitalSV Health InvestorsDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.British Business Bank+3 more
Empirico is a clinical-stage biotechnology company that pairs human genetics-driven target discovery with siRNA medicine development to create genetic medicines for common diseases with unmet need.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
Omri Gottesman(Co-Founder; Chief Executive Officer and President)Shannon Bruse(Co-Founder; SVP, Head of Target Discovery and Biology)Brian Cajes(Co-Founder; SVP, Head of Data Platforms and Engineering)Bill McLeod(Chief Financial Officer)Michael Molyneaux(Chief Medical Officer)David Lewis(SVP, Head of Drug Discovery and Development)
Co-investorsNeotribe VenturesQiming Venture Partners
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.
BiotechHealthtechLongevity
Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)
Co-investorsMPM BioImpactVersant VenturesLilly Asia VenturesDCVC (Data Collective)
BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.
BiotechData & InfrastructureEnterprise SoftwareMedia & EntertainmentDurham, US
Pieter Burger(Executive Officer, Director)inThomas Kaiser(Executive Officer, Director)in
BoardChristopher Meldrum(Executive Officer, Director)inDennis Langer(Director)
Board seatJohn Hamer· per SEC Form D
Elo develops plant-based food ingredients and technologies to enhance nutritional value, taste, and climate resilience in everyday foods.
AgTechBiotechClimate TechFoodTechNew MaterialsDurham, US
ToddMichele Fite(Executive Officer)inMatthew Todd Rands(Executive Officer, Director)Chloe Pavely(Executive Officer)inMatt DiLeo(Director)inPaul Boyer(Executive Officer)in
Board seatKiersten Stead· per SEC Form D
Co-investorsDCVC (Data Collective)Accelr8KdT VenturesNovo Holdings
Empirico is a San Diego-based clinical-stage biotech that uses human genetics data and computational methods to discover disease targets and develop siRNA and antibody therapeutics.
BiotechSan Diego, US
Omri Gottesman(Executive Officer, Director)Shannon Bruse(Executive Officer, Director)Brian Cajes(Executive Officer)
BoardKolluri Swaroop(Director)
Board seatJohn Hamer· per SEC Form D · $55.2M raise · filed Mar 2023
Co-investorsDCVC (Data Collective)Felicis VenturesQiming Venture Partners USA
MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.
BiotechCircular EconomyNew MaterialsEmeryville, US
Philip Ross(Founder)inMichael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)inEddie Pavlu(Founder)Phil Ross(Founder)Sophia Wang(Founder)
Board seatKiersten Stead· per SEC Form D
Co-investorsATEL VenturesDCVC (Data Collective)Hemisphere Ventures LLCValor Equity PartnersWireframe Ventures8VC+8 more
Unlearn develops AI-powered digital twins and data analytics tools to optimize clinical trial design and execution for pharmaceutical companies.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSan Francisco, US
Charles Fisher(Founder)inAaron Smith(Founder)inJonathan Walsh(Founder)
Board seatJohn Hamer· per SEC Form D
Co-investors8VCAlumni VenturesBasecamp FundDCVC (Data Collective)Eisai Innovation, Inc.Flucas Ventures+6 more
AgZen develops real-time monitoring technology for crop spraying, analyzing droplet behavior to help growers and agricultural equipment manufacturers optimize application efficiency.
AgTechAI & Machine LearningFintechHardwareImpact & Social GoodMedia & EntertainmentSomerville, US
Vishnu Jayaprakash(Founder)inKripa Varanasi(Director)inMaher Damak
BoardCarmichael S. Roberts(Director)Justin Kern(Director)
Co-investorsAstanor VenturesMaterial ImpactDCVC (Data Collective)Syngenta Group Ventures
BiotechNewton, US
Katharine Yen(Executive Officer, Director)Kate Yen(Founder)inChristopher Guiffre(Executive Officer)
BoardAlon Lazarus(Director)Anna French(Director)inAlexandra Cantley(Director)in
Co-investorsDCVC (Data Collective)Qiming Venture Partners USAApollo Health VenturesBrightEdgePolaris PartnersQiming Venture Partners
CH4 Global develops greenhouse gas mitigation solutions centered on Asparagopsis seaweed, producing feed supplements that reduce enteric methane emissions from cattle for the livestock and agriculture industries.
AgTechCleantechClimate TechFoodTech
Steve Meller(CEO, President & Co-Founder)in
Co-investorsCleveland AvenueDCVC (Data Collective)AgFunder
Creyon develops aptamer-delivered oligonucleotide therapeutics for targeted cell-specific delivery, including small interfering RNA and antisense oligonucleotides.
AI & Machine LearningBiotechDeep Tech
Matthew Levy(Co-founder)in
Co-investorsLux CapitalTenmile
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease.
AI & Machine LearningBiotechDeep Tech
Co-investorsBioBritDCVC (Data Collective)TenmileAlexandriaCasdin CapitalLux Capital
DCVC is a deep technology venture capital firm that invests in entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, robotics, space, biology, and defense.
AI & Machine LearningClimate TechDeep Tech
Matt Ocko(Founder and Managing Partner)inZachary Bogue(Founder and Managing Partner)Dr. John Hamer(Co-founder and Managing Partner, DCVC Bio)Dr. Kiersten Stead(Co-founder and Managing Partner, DCVC Bio)
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesFelicis VenturesMPM BioImpactRA Capital+2 more
Greater Long Island is a local news and media outlet publishing stories and coverage about Long Island communities.
Media & Entertainment
Grove Biopharma develops Bionic Biologics, a drug discovery platform combining AI-enabled molecular design, precision polymer chemistry, and experimental biology to target protein-protein interactions that are inaccessible to conventional therapeutics.
AI & Machine LearningBiotechDeep TechChicago, US
Geoffrey Duyk(CEO)in
Co-investorsDCVC (Data Collective)InVivium CapitalPortal InnovationsDeepWork Capital
Latus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise.
AI & Machine LearningBiotechDeep TechHealthtechPhiladelphia, US
Co-investorsHatch BioFund8VCBioAdvanceDCVC (Data Collective)GaingelsKorea Development Bank+1 more
__Twitter.png)
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas VentureNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime Capital+11 more
BiotechBoston, US
David Donabedian(Executive Officer, Director)inRobert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardChristoph Westphal(Director)Ming Cheah(Director)inRaymond Camahort(Director)
Co-investorsDCVC (Data Collective)Arkin CapitalLongwood FundNovo Holdings
The New Yorker is a magazine and digital publication producing reporting, criticism, essays, fiction, and cultural commentary, along with puzzles, podcasts, and cartoons.
Media & Entertainment
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechNew York, US
Jeff Goater(Executive Officer, Director)inKim Seth(CEO)in
BoardTim Kutzkey(Executive Officer, Director, Promoter)in
Co-investorsDCVC (Data Collective)The Column GroupAlexandriaLux Capital
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners VenturesColorcon Ventures5AM VenturesAlexandriaDCVC (Data Collective)+1 more
Radionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Diego, US
Brett Ewald(Chief Operating Officer, Founding Member)inAlyssa Levin(Chief Financial Officer)inPaul Grayson(Chief Executive Officer)in
Co-investors5AM VenturesFrazier Life Sciences
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life Sciences5AM VenturesFrazier Healthcare PartnersWestlake Village BioPartners
Sabanto retrofits existing tractors with an aftermarket autonomy system so growers can run field operations without a driver.
Craig Rupp(Founder)in
Co-investorsCavallo VenturesCerity Partners VenturesDCVC (Data Collective)Fulcrum Global CapitalLeaps by BayerTrimble Ventures+1 more
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Frazier Life SciencesLongwood FundNovartis Venture FundOrbiMed+2 more
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.
BiotechDeep TechMedical DevicesChicago, US
Ryan Clarke(Co-Founder, Chief Scientific Officer)inNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)Matt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inPatrick Shaddow(Executive Officer, Director)John Craighead, PhD(Chief Executive Officer)
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Draper AssociatesIllumina VenturesPortal InnovationsWalder Ventures
Totus Medicines is a biopharmaceutical company developing small molecule drugs to address untreatable diseases by combining approaches in molecular design, structural biology, genetics, and cell biology.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Neil Dhawan, PhD(Co-Founder)Nassim Usman, PhD(CEO and President)
Co-investorsDCVC (Data Collective)Social Impact Capital
Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution.
AI & Machine LearningBiotechDeep Tech
Co-investorsBlueYard CapitalJAZZ Venture PartnersARCH Venture PartnersInsight PartnersMayo Clinic Ventures
Verdant is a software platform that manages the full planning and permitting workflow for local government agencies, from resident inquiries through final commission votes.
AI & Machine LearningGovTechSan Francisco, US
Aidan Ng(Founder)inJason Yi(Founder)in
Co-investorsY CombinatorAgFunderAutotech VenturesCavallo VenturesCleveland AvenueDoomers Media LLC+4 more
Verdant Robotics builds the SharpShooter, a precision agriculture system that uses machine vision to detect individual plants and apply targeted micro-shots of herbicide or other inputs, replacing broadcast spraying, manual weeding, and thinning.
AgTechAI & Machine LearningRoboticsHayward, US
Gabe Sibley(Founder)inCurtis Garner(Founder)inLawrence Ibarria(Founder)inDavid(Technology leader)inGabe Sibley Curtis Garner(Founder)
BoardKiersten Stead(Director)in
Co-investorsATEL VenturesCavallo VenturesCleveland AvenueDCVC (Data Collective)Doon CapitalFuture Ventures+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Epsilon Holdings, Inc.Ascend Gene & Cell TherapiesBioPheroSolu Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
1 IPOs · 1 acquisitionsFervo EnergyNASDAQ: FRVOBioPheroacq. by FMC
Portfolio news
latest coverage across their companiesTranscripta Bio · finsmes.com · Jul 23, 2026
Sabanto · finsmes.com · Jul 14, 2026
Alchemab · trysignalbase.com · Jul 10, 2026
Verdant · ycombinator.com · Jul 7, 2026
Latus · finsmes.com · May 5, 2026
Nilo Therapeutics · finsmes.com · Oct 9, 2025
Fund performance · per public LP disclosures
as of Nov 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| DCVC Bio II, L.P.LPs: Employees' Retirement System of Rhode Island | 2020 | — | 3.5% | 1.07x | 0.21x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has DCVC Bio made?
- DCVC Bio has 38 tracked investments, 2 of which have exited, including 10 dated in the last 24 months.
- What stage does DCVC Bio invest at?
- DCVC Bio invests at the Seed, Series A, Series B, Growth stages.
- What sectors does DCVC Bio focus on?
- DCVC Bio focuses on Advanced Manufacturing, AgTech, AI & Machine Learning, Biotech, Climate Tech, Cybersecurity, Deep Tech, Defense Tech, Energy, Fintech, FoodTech, InsurTech, Longevity, New Materials, Quantum Computing, Space Tech.
- Where is DCVC Bio located?
- DCVC Bio is headquartered in Palo Alto, US.
- Who does DCVC Bio co-invest with?
- DCVC Bio most often shares deals with DCVC (Data Collective), Astellas Venture Management LLC, Portal Innovations, among 26 tracked co-investors.
Images
Similar investors
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
This page is the analysis and research library of BDC (Business Development Bank of Canada), listing studies, surveys and reports on issues affecting Canadian small and medium-sized businesses and the venture capital landscape.
Everywhere Ventures is an early-stage venture firm that writes pre-seed checks and is backed by a community of founder and operator LPs.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Prime Movers Lab is an early-stage venture capital firm that invests in startups advancing breakthrough scientific and engineering innovations.